Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Drug Hypersensitivity Consortium - (Author)
  • Stanford University
  • National Institutes of Health (NIH)
  • University of California at San Diego
  • Children's Healthcare of Atlanta
  • University of Pittsburgh
  • Children's Hospital and Regional Medical Center Seattle
  • National Human Genome Research Institute
  • University of Pennsylvania
  • Pennsylvania State College of Medicine (PSCOM)
  • Emory University
  • Yale University
  • The University of Hong Kong
  • University of California at San Francisco

Abstract

OBJECTIVES: Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, delayed hypersensitivity reaction (DHR). We observed DRESS to inhibitors of interleukin 1 (IL-1) or IL-6 in a small group of patients with Still's disease with atypical lung disease. We sought to characterise features of patients with Still's disease with DRESS compared with drug-tolerant Still's controls. We analysed human leucocyte antigen (HLA) alleles for association to inhibitor-related DHR, including in a small Kawasaki disease (KD) cohort.

METHODS: In a case/control study, we collected a multicentre series of patients with Still's disease with features of inhibitor-related DRESS (n=66) and drug-tolerant Still's controls (n=65). We retrospectively analysed clinical data from all Still's subjects and typed 94/131 for HLA. European Still's-DRESS cases were ancestry matched to International Childhood Arthritis Genetics Consortium paediatric Still's cases (n=550) and compared for HLA allele frequencies. HLA association also was analysed using Still's-DRESS cases (n=64) compared with drug-tolerant Still's controls (n=30). KD subjects (n=19) were similarly studied.

RESULTS: Still's-DRESS features included eosinophilia (89%), AST-ALT elevation (75%) and non-evanescent rash (95%; 88% involving face). Macrophage activation syndrome during treatment was frequent in Still's-DRESS (64%) versus drug-tolerant Still's (3%; p=1.2×10-14). We found striking enrichment for HLA-DRB1*15 haplotypes in Still's-DRESS cases versus INCHARGE Still's controls (p=7.5×10-13) and versus self-identified, ancestry-matched Still's controls (p=6.3×10-10). In the KD cohort, DRB1*15:01 was present only in those with suspected anakinra reactions.

CONCLUSIONS: DRESS-type reactions occur among patients treated with IL-1/IL-6 inhibitors and strongly associate with common HLA-DRB1*15 haplotypes. Consideration of preprescription HLA typing and vigilance for serious reactions to these drugs are warranted.

Details

Original languageEnglish
Pages (from-to)406-415
Number of pages10
JournalAnnals of the rheumatic diseases
Volume81
Issue number3
Publication statusPublished - Mar 2022
Peer-reviewedYes
Externally publishedYes

External IDs

PubMedCentral PMC10564446
Scopus 85122311963

Keywords

Sustainable Development Goals

Keywords

  • Adult, Alleles, Antirheumatic Agents/adverse effects, Case-Control Studies, Drug Hypersensitivity Syndrome/genetics, Drug Tolerance/genetics, Female, HLA-DRB1 Chains/genetics, Haplotypes, Humans, Hypersensitivity, Delayed/genetics, Interleukin-1/antagonists & inhibitors, Interleukin-6/antagonists & inhibitors, Male, Mucocutaneous Lymph Node Syndrome/drug therapy, Retrospective Studies, Still's Disease, Adult-Onset/drug therapy